Divergent Planning LLC Invests $694,000 in Novartis AG $NVS

Divergent Planning LLC acquired a new stake in shares of Novartis AG (NYSE:NVS) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 5,739 shares of the company’s stock, valued at approximately $694,000.

Several other large investors have also bought and sold shares of the company. WPG Advisers LLC purchased a new stake in shares of Novartis during the first quarter valued at approximately $25,000. Tsfg LLC lifted its position in Novartis by 366.0% in the 1st quarter. Tsfg LLC now owns 233 shares of the company’s stock valued at $26,000 after acquiring an additional 183 shares in the last quarter. GFG Capital LLC bought a new position in Novartis in the 2nd quarter valued at approximately $26,000. Barrett & Company Inc. purchased a new stake in Novartis during the 2nd quarter valued at $31,000. Finally, MCF Advisors LLC increased its holdings in shares of Novartis by 66.0% in the 2nd quarter. MCF Advisors LLC now owns 264 shares of the company’s stock worth $32,000 after purchasing an additional 105 shares in the last quarter. 13.12% of the stock is owned by hedge funds and other institutional investors.

Novartis Price Performance

Shares of NYSE:NVS opened at $131.78 on Tuesday. The firm’s 50 day moving average price is $126.80 and its 200-day moving average price is $118.80. The company has a quick ratio of 0.62, a current ratio of 0.82 and a debt-to-equity ratio of 0.53. The stock has a market capitalization of $278.38 billion, a PE ratio of 19.18, a price-to-earnings-growth ratio of 1.82 and a beta of 0.64. Novartis AG has a twelve month low of $96.06 and a twelve month high of $133.55.

Analyst Upgrades and Downgrades

NVS has been the topic of a number of research analyst reports. The Goldman Sachs Group reaffirmed a “sell” rating and set a $118.00 price target (down from $119.00) on shares of Novartis in a report on Friday, September 12th. Wall Street Zen upgraded Novartis from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 11th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Novartis in a research note on Thursday, August 21st. Morgan Stanley raised shares of Novartis from an “underweight” rating to an “equal weight” rating and set a $123.00 price target on the stock in a report on Friday, August 8th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Novartis in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, four have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, Novartis presently has an average rating of “Hold” and a consensus target price of $120.33.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.